Revance Therapeutics, Inc. 4
4 · Revance Therapeutics, Inc. · Filed Sep 4, 2015
Insider Transaction Report
Form 4
Bertolino Arthur Peter
EVP and Chief Medical Officer
Transactions
- Tax Payment
Common Stock
2015-09-02$30.48/sh−3,699$112,746→ 41,754 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on September 2, 2015, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Award ("RSA") for 9,844 shares. The RSA vests in four equal annual installments from September 2, 2014, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.